Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells-Reference-Cited by-同舟云学术

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

Published:2020-01 Issue:1 Volume:26 Page:26-33
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Cordeiro Ana,Bezerra Evandro D.,Hirayama Alexandre V.,Hill Joshua A.,Wu Qian V.,Voutsinas Jenna,Sorror Mohamed L.,Turtle Cameron J.,Maloney David G.,Bar Merav

Funder

National Cancer Institute

National Institute of Diabetes and Digestive and Kidney Diseases

National Heart, Lung, and Blood Institute

Indiana University

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference29 articles.

1. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia;Maude;N Engl J Med,2018

2. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

3. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

4. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells;Turtle;Sci Transl Med,2016

5. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo;Sommermeyer;Leukemia,2016

Cited by 249 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01

2. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome;Pharmaceutical Research;2024-08-26

3. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention;Frontiers in Immunology;2024-08-26

4. Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBase;2024-08-09

5. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium;Journal of Clinical Oncology;2024-08-02